Increasing prevalence of hypertension is expected to propel growth of the renal denervation devices market
In the treatment of uncontrolled or persistent hypertension,
if hypertensive medicine is unsuccessful, renal denervation devices play a
significant role in contemporary healthcare. A catheter used in the operation
emits radiofrequency energy across several electrodes.
A significant driver of the renal denervation industry is
the rise in clinical trials for the treatment of diseases including
hypertension and blood pressure. This increase in trials is anticipated to
increase the demand for renal denervation and present new prospects for Renal
Denervation Devices market
participants. It is anticipated that new clinical trials will provide a scope
of development in advanced economies like Europe and the United States. For
instance, the ongoing RADIANCE-HTN trial in Connecticut is being pioneered by
Stanford Health. Several centres in Europe and the United States are connected
to the multicenter, worldwide trial.
The constraints of a renal denervation system based on
radiofrequency can be overcome by using ultrasound technology. Without directly
touching the tissues, the high-frequency sound waves of the ultrasound energy
aid in the ablation of the nerves. This lessens injury to the renal arteries.
Comments
Post a Comment